Brock: My name is Brock and I will be your conference facilitator this afternoon. At this time, I would like to welcome everyone to Fordham Corporation's third quarter 2025 earnings results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press star then the number one on your telephone keypad. If you would like to withdraw your question, please press star 2. I would now like to turn the call over to Ms. Christina Jones, Vice President of Investor Relations. Ms. Jones, you may begin your conference.
Christina Jones: Thank you, and thank you, everyone, for joining us on today's call. I am joined today by Illumide Charoyer, Board of President and CEO, and Mark Okerstrom, Board of CFO. As a reminder, we successfully completed the separation of our precision technology segment, now operating independently as Rallions, on June 28, 2025. Today's call marks Fortiv's first quarterly results under our new structure. During today's call, we present certain non-GAAP financial measures. Information required by Regulation G is available on the Investors section of our website at fortiv.com. We will also make forward-looking statements, including statements regarding events or developments that we expect or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks, and actual results might differ materially from any forward-looking statements that we make today. Information regarding these risk factors is available in our FAC filings including our annual report on Form 10-K and the subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements. Our statements on period-to-period increases or decreases refer to year-over-year comparisons, unless otherwise specified. Our results and outlook discussed today are on a continuing operations basis, unless otherwise specified. With that, I'll turn the call over to Illuminae.
Illuminae Charoyer: Thank you, Christina. Let me begin on slide three with a few key messages. Q3 was our first quarter as New 40, following our successful spin off of rallying. We are now a simpler, more focused company with a clear strategy, poised to create meaningful share of the value. Our Q3 results offer a waypoint along our path towards creating exceptional returns for shareholders in the years ahead. Four highlights I would like to call out. First, our teams are executing very well with laser focus on driving profitable organic growth with the power of our 40th business system. This drove solid results ahead of our expectations, including core growth of roughly 2%, adjusted EBITDA growth of 10%, and adjusted EPS growth of 15%. Though we aspire for much better as we continue executing our growth strategy, we're pleased to see acceleration in the business. Second, we are raising our full-year adjusted EPS guidance. We now expect to deliver between $2.63 and $2.67 per share, reflecting our adjusted EPS overperformance in the third quarter, the impact of incremental Q3 buybacks, and our otherwise unchanged view on Q4. Third, we deployed capital in the quarter in accordance with our new approach, anchored in delivering the strongest relative returns for shareholders. During the third quarter, we deployed $1 billion to share repurchases, retiring approximately 21 million shares, or 6% of our fully diluted share count. Finally, the financial framework we outlined at our June investor day remains fully intact. And our 40 accelerated strategy is now in execution mode. We have focused on delivering benchmark-beating shareholder returns by leveraging FBS to accelerate profitable organic growth, allocating capital intelligently to optimize shareholder returns over the medium to long term, and rebuilding investor trust. It is early days, but we couldn't be more excited for the road ahead. Before we dive into our Q3 results, let me highlight some examples of the progress we are making in executing our 40th Accelerator Strategy on slide four. Our strategy to drive fast organic growth is built around three core levers, innovation acceleration, commercial acceleration, and recurring customer value, all powered by our amplified 40 business system and enhanced by our disciplined capital allocation approach. We made meaningful progress in advancing our strategy in Q3, starting with innovation acceleration. Our new product introduction velocity continues to accelerate as a result of our renewed focus on customer-centric innovation. During the quarter, we had several notable product launches, including Service Channel's SaaS R2 release, which introduces AI-powered work order insights and streamlined payment solutions. Additionally, Fluke continued its innovation momentum with the GFL-1500 solar ground fault locator. This marks a further foray into the high-growth solar operations vertical and increases customer productivity by reducing troubleshooting time and decreasing hazard exposures. In the quarter, we also launched a new innovation studio in Nashville, Tennessee, and opened a new customer experience center at ASP's headquarters in Irvine, California. Both purpose-built to foster collaboration, accelerate innovation, and deepen customer relationships. Turning to commercial acceleration, we further intensified our commercial focus on faster-growing end markets and regions. And though it is early, we are starting to see green shoots in several areas. In our iOS segment, for example, we have begun to put in place a series of commercial initiatives in North America to enhance our focus and deploy more resources towards high-growth verticals like solar operations, distributed energy, data centers, and defense. We are seeing the early signs of impact in North America Q3 performance. We also recently stepped up our efforts in South Asia, including India, as that region continues to see exceptional economic growth. We saw significant acceleration in the region across both segments, And we are confident that our enhanced regional presence will drive strong momentum in this high growth region in the years to come. Moving on to recurring customer value, we remain focused on increasing recurring revenues. Here again, we are early in our journey and have meaningful runway ahead of us. In the quarter, Fluke continued to make great progress on increasing its percentage of recurring revenue through enhancements to our maintenance software and further expansion of our service plan offerings. And in general, we saw recurring revenue growth continue to outpace our consolidated growth. Finally, disciplined capital allocation is an integral component of our FortiVa Accelerated Strategy. Our capital deployment priorities for New FortiVa are clear. Invest in organic growth, pursue accretive bolt-on M&A, return capital through share repurchases, and maintain a modest growing dividend, all with a focus on best relative returns and maximizing medium to long-term shareholder value. Consistent with these priorities, we repurchased about 21 million shares in the third quarter, reflecting our belief in the attractive relative return of share buybacks at the valuations we saw in the quarter. We have also revamped our M&A funnel and process to reflect our different M&A strategy going forward, focused on accretive, smaller, bolt-on M&A, which meet our stringent strategic and financial criteria. With that, I'll turn it over to Matt to walk through our financial results for the third quarter. Thanks, Olimide.
Mark Okerstrom: I'll begin with slide five. In the third quarter, we delivered total revenue of just over $1 billion, up roughly 2% year-over-year on both a reported and a core basis. While market conditions remain dynamic, we were encouraged to see growth at both iOS and AHS and modest outperformance versus our expectations in both segments. In iOS, resilient customer demand drove better-than-expected results at both Fluke and our facilities and asset lifecycle software businesses. In AHS, healthcare customers continue to exhibit caution as they navigate recent changes to healthcare reimbursement and funding policy. However, we saw sequential improvement in demand for healthcare equipment and consumables and continued strength in healthcare software. From a geographic perspective, North America showed solid growth, improving sequentially from Q2, driven by strengthening demand trends for professional instrumentation and healthcare equipment. Europe was down year over year and worsened modestly from Q2, driven by weakening macro conditions in the region. The rest of the world was mixed. Adjusted gross margin in the quarter was down about 60 basis points driven by tariff-related costs, partially offset by pricing actions and supply chain countermeasures. Adjusted EBITDA was $309 million, up 10% year-over-year, with growth accelerating from Q2 levels. Adjusted EBITDA margin expanded approximately 200 basis points to 30%. This strong operational performance was driven by operating leverage alongside deliberate organizational streamlining and an overall sharpened focus on corporate cost discipline. We delivered adjusted EPS of 68 cents up 15% year-over-year, a meaningful acceleration from Q2, driven by growth in adjusted EBITDA, favorable interest expense on lower debt balances, and the positive year-over-year impact of share repurchases. We estimate direct tariff costs net of countermeasures. created a roughly $0.01 headwind to adjusted EPS in the quarter. We generated $266 million of free cash flow in the third quarter, and our Q3 trailing 12-month free cash flow grew to $922 million. Our Q3 trailing 12-month free cash flow conversion on adjusted net income remains comfortably north of 100%. Moving to our segment results, starting with intelligent operating solutions on slide 6, Revenue for the segment grew just over 2.5% on a reported basis, with core revenue growth of 2% slightly ahead of our expectations. Growth was driven by demand for facility and asset lifecycle software, resilient demand for professional instrumentation despite tariff volatility, and strong growth in gas detection products. At Fluke, we saw an improvement in customer purchasing patterns drive modest growth, with particular strength in North America, partially offset by continued softness in Europe related to macro conditions. While the acceleration is encouraging, ongoing volatility in global trade policy remains a source of uncertainty. Our facilities and asset lifecycle software businesses perform modestly ahead of expectations, supported by strong demand for multi-site facility maintenance and marketplace software in North America, However, tighter fiscal policy and constrained funding continue to pressure government demand for our procurement and estimating solutions. Our gas detection business is growing nicely with strong demand for a hardware-as-a-service model to ensure worker safety with particular strength in North America and Latin America. Adjusted gross margin in the segment declined by just over 90 basis points year-over-year to 65.7%, primarily due to tariff cost pressures partially offset by pricing and supply chain countermeasures. Adjusted EBITDA grew 7% to $242 million, accelerating from the more modest growth we saw in Q2, driven by operating leverage and reduced costs associated with flattening and rationalizing segment-level organizational structures. Adjusted EBITDA margin grew to 34.6%, up from 33.3% in the prior year period. Moving to our Advanced Healthcare Solutions segment on slide 7, we delivered total revenue of $328 million. Revenue grew approximately 2% year-over-year, just over 1% on a core basis. As we noted last quarter, we continue to see reimbursement and funding policy changes impact the AHS segment, specifically the deferral of U.S.-based hospital capital expenditures on healthcare equipment. However, demand trends in North America improved from Q2 levels, driving sequential improvement in capital performance as some customers executed on deferred orders for sterilization and biomedical test equipment. Consumables demand also improves sequentially across most regions. Encouragingly, our software products in the segment continue to deliver solid growth, fueled by strong execution and structural advantages from resilient SaaS-based revenue models. Our adjusted gross margin of 58.4% in the AHS segment was similar to last year. Adjusted EBITDA grew approximately 7% year-over-year. Adjusted EBITDA margin expanded from roughly 27% to 28%, driven by operating leverage, flattened organizational structures partially offset by modest incremental R&D investments. Turning to slide 8, as noted earlier, we deployed just over $1 billion of capital to share repurchases in the third quarter. reflecting confidence in our ability to deliver on the core value creation plan represented by our forward of accelerated strategy and the attractive valuations we saw in the quarter. We funded these repurchases with a combination of the remaining proceeds from the rally and spin-off dividend, cash on hand, and increased commercial paper issuance in anticipation of continued strong free cash flow generation in the quarters ahead. As previously highlighted, our free cash flow on a 12-month basis was $922 million. Moving to slide 9, we are raising our full-year adjusted EPS guidance to $2.63 to $2.67 per share. Our guidance reflects Q3 results ahead of our expectations, the impact of incremental buybacks in Q3, and otherwise no change to the view we held on Q4 as at our last earnings call. This outlook also assumes a continuation of the market dynamics we experienced as we exited Q3. It also reflects current or known future tariff rates expected to go into effect through the end of the year, with tariffs net of countermeasures not expected to be material in the quarter. Let me provide a few additional modeling considerations. Based on what we see today, we are expecting overall core growth to moderate in Q4, with AHS core growth broadly in line with Q3 levels and very modest core growth at IOS. We continue to expect a full-year adjusted effective tax rate in the mid-teens and a Q4 tax rate in the single digits due to discrete tax items in the quarter. We also expect a sequential increase in net interest expense in Q4, reflecting our cash and debt levels at quarter end. As a final note before turning it back to Illuminae for closing remarks and Q&A, in our first quarter post-spinoff, we took important first steps to demonstrate our steadfast commitment to unrelenting execution on the Ford of Accelerated three-pillar value creation plan that we outlined at our June Investor Day. We have much work left to do, but change is underway and we are energized by the exciting work ahead of us. I'll now turn it back over to Illuminae.
Illuminae Charoyer: Thanks, Mark. I'll close out our prepared remarks with a few reflections from my first quarter as CEO and offer a bit more color on the changes we have catalyzed at Fortiv in the past 100 days. First, our thesis behind the creation of new Fortiv as a simpler, more focused company is showing promising early outcomes. We are seeing the benefits of simplification in our day-to-day operations, enabling us to be notably more customer-centric. With fewer operating brands, we've been able to simplify our organizational model and processes. That is freeing up more time across our team to focus on the source of growth, our customers. Personally, I have really enjoyed spending significantly more time with our customers across both segments as we deepen relationships and uncover additional opportunities to accelerate growth. We have also flattened out our executive leadership team to ensure that business leaders in closest proximity to our customers have a stronger voice at the top of our company. With 100,000 customers across our portfolio, I am energized by the impact our enhanced customer-centric approach will have on our growth trajectory. Second, we are taking deliberate steps to accelerate growth. We are giving our 10 operating brands more growth oxygen and encouraging them to freely and frequently surface the next best organic growth opportunity that may have been underexploited in the past. We have transformed our strategic planning process into a more aggressive growth-focused engine, and we are emerging from our recent strategic planning cycle with a robust pipeline of investable growth opportunities. And we are re-gearing our annual financial planning, forecasting, and governance processes to enable in-year investment into growth as overperformance materializes. Third, our 40 business system is powerful, not just for leadership and lean, but as a systematic growth engine. We are making great progress in evolving the mindset, cadence, and tools of FBS to better support growth, not just by integrating our AI center of excellence directly into our FBS team, but also by evolving and enhancing existing tool sets and best practices around innovation, commercial acceleration, and creating recurring customer value. Finally, our new approach to capital allocation is very different from what it was in the past. Our dynamic and disciplined capital allocation approach has one singular purpose, maximizing medium to long-term shareholder returns. And we have demonstrated our commitment to this approach in our first quarter as New Fordy. We are pleased with our results this quarter, but we are not satisfied. We are driving hard towards our ambitious agenda and look forward to demonstrating continued and accelerated progress in the quarters and years ahead. Thank you for your continued interest in 40th. I especially want to thank our shareholders, our 100,000 customers, and all our 40th employees around the world who do a tremendous job every day to deliver strong results and build enduring advantages in our businesses. With that, I'll turn it to Christina for Q&A.
Christina Jones: Thanks, Illuminae. That concludes our prepared remarks. We are now ready for questions.
Brock: Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Our first question today comes from Nigel Coe of Wolf Research. Please proceed with your question.
Nigel Coe: Oh, thanks. Good morning. Good afternoon, even. It's been a long day. Thanks for the details. Obviously, you know, the margin performance was, to my mind, the real highlight. And it seems, you know, when I look at your sort of implied 4Q guide, it looks like you're not assuming much of a sequential pickup in EBITDA margins. I mean, we're back into something in the range of about 31% EBITDA margin for the fourth quarter. So just as curious, is there any sort of, you know, was it a sort of stars aligning kind of quarter on margin and you're not assuming that repeats? Any kind of details there, especially around some of the tariff offsets you expect in 4Q?
Mark Okerstrom: Hey, Nigel. How are you? Thanks for the question. So if you think about the overperformance we delivered in Q3, a part of it was revenue of performance because you called out a big chunk of it was cost discipline. And you can see that show up in the numbers both in unallocated corporate costs and also in the segments. Most of that was actually discrete actions that we took in the quarter really to start to free up resources for us ahead of annual planning so that we could deploy against some of the initiatives that we're starting to see as part of the Ford have accelerated strategy to accelerate growth into 2026. So we do expect to redeploy some of the resources we freed up in the fourth quarter. There were a few little one-timers, incentive compensation, some increased capitalization of software development that happened in the quarter. We're going to maintain our cost discipline through the fourth quarter to be sure, but we are going to reinvest some of it as we look forward here.
Nigel Coe: Okay, that's a good call-out. And then my follow-on is really around the government shutdown. I think we hit the fourth week today. You called out some government funding pressure within Gordian. Just curious how that's impacting performance in October.
Illuminae Charoyer: Yeah, thanks, Nigel. So the government's business for us is mostly state and local government agencies. So in that sense, the federal government shutdown is not a big factor. Our direct exposure to federal government is relatively small, just a little bit in our file business and fluke and AHS. So it really just hasn't been a major factor for us right now. It's difficult to predict the duration of the shutdown and second level impacts of a prolonged shutdown. But we feel good about the guidance based on what we know today. And again, given it's not a big direct exposure to the federal government, for us, we feel good about what we've laid out.
Nigel Coe: That's great to hear. Thank you.
Brock: Thanks. The next question is from Dean Dre of RBC Capital Markets. Please proceed with your question.
Dean Dre: Thank you. Good day, everyone.
Brock: Hi, Dan.
Dean Dre: I was hoping just to circle up on capital allocation. That was a sizable buyback in the quarter. Just kind of give us your thinking about the decision making on doing buybacks. Is there intrinsic value calculation you're doing internally? And then just the setup for M&A, because you had been through this moratorium on deal making. leading up to the spin, where does that stand in priorities? Thank you.
Illuminae Charoyer: Yeah, thanks for the question, Dane. So we were quite pleased to be able to deploy a billion dollars towards share repurchase in Q3. And that reflected just a strong free cash flow, the rally in dividend proceeds and Just, you know, the attractive valuation we saw for our shares in the quarter. And like we've mentioned with respect to 40 going forward, share repurchases will be a big part of our capital allocation option set. So anytime we see conditions like that, we'll continue to do that. To the extent that M&A is still part of our formula, we've been quite clear that we are not looking at transformational M&A. We're looking at smaller bolt-on acquisitions that can accelerate the go-forward growth of our existing businesses. So it's a very different playbook on M&A. We are going to be more balanced across share approaches and this bolt-on M&A acquisitions that we do. Like we mentioned at our investor day, the formula we laid out for shareholder value creation the next three years does not require us to do M&A. So from our point of view, we're going to take the path that offers the lowest risk to create value, and that for us does not include big M&A. So we continue to cultivate our funnel of proprietary bolt-on assets that are smaller and can help our existing businesses. But that's how we think about it. We do the analysis to your point of what gives us the best relative returns between share repurchase and the M&A options that we have. And in the third quarter specifically, the case was very clear just given where the stock price was to deploy that heavy billion-dollar surrey purchases.
Dean Dre: That's really helpful. And just as the second question was hoping to get some color on fluke in the quarter, it's such a good indicator of short cycle demand. So anything about the sell-in versus sell-through channel inventory would be helpful. Thanks.
Illuminae Charoyer: Yeah, no, thanks. Thanks. And so we were quite pleased with Fluke in the quarter and having it return to growth in the quarter. All the fundamental metrics That set up the future, looked really strong. We had other growth. POS continues to be really strong, especially in North America and stable in the rest of the world. Book to bill for the year continues to track north of one. Channel inventory outside of North America, we've said all year, been elevated, but that's been improving over the course of the year, so we're in a much better place than We were at the beginning of the year. And then on top of that, our team continues to accelerate product innovation. I talked about a couple of those in the prepared remarks. And also commercial execution. There's some markets, both verticals like data center and defense, that are doing really well right now. And also geos like India that are doing very well. Our team continues to put a lot more horsepower behind those markets. And then we're driving more recurring revenues at Fluke. with our maintenance software enhancements and additions to our service plans. So both by reason of how we did in Q3 at Fluke, the underlying metrics of the health of the business, and then the actions the team's doing to really continue to accelerate growth, we feel quite good about the setup for the next three years at Fluke.
Dean Dre: That's really helpful. Thank you.
Brock: Thanks. The next question is from Scott Davis of Mielus Research. Please proceed with your question.
Scott Davis: Hey, guys, and congrats on the first full quarter. It was pretty clean. Hey, guys, one of your competitors has been getting a lot of attention in the radiation test business, and I haven't heard you all talk about Landauer in a while. Can you get us up to speed on the outlook there and what you're seeing?
Illuminae Charoyer: Yeah, thank you, Scott. So, you're right. You know, there's a lot of excitement in the Landau business for us. As you know, it's one of the highly recurring parts of our AHS segment. So, we like that attribute of a business. And, you know, we've said the recurring part of the company for the overall has been growing faster than our fleet average. And Landau is a great example of that. So, it's continued to to grow really strongly, and that comes from the fact that customers really rely on us for this mission-critical radiation monitoring. It's a very stable need for customers. They're looking for really the number one brand that they can trust, and that helps joint commission reviews and other regulatory requirements they have to meet be much easier to meet. So we see a lot of strength in that business. The thing that I find exciting for us is the work that our team is doing on innovation. And that includes finding add-on services that we can tag onto our existing customer base. We have tens of thousands of customers in that business. And so the idea of thinking about that business like a software business that you can add on to existing customers besides price and expansion to other customers. Sorry, you're breaking up. I can't hear you.
Brock: Are you there, fellas?
Illuminae Charoyer: Yes. Can you hear us?
Scott Davis: It's breaking up. It could be our phone. It could be you guys. I don't know. I'll pass it on because I don't want to be disruptive to the call.
Christina Jones: Brock, are you hearing us okay?
Brock: Yes, you're coming through loud and clear, and we'll move on to the next question. I'll pass it to Julian Mitchell of Barclays. Please proceed with your question.
Julian Mitchell: Hi, good afternoon. Maybe just wanted to follow up on the demand trends in AHS. You know, maybe help us understand sort of what's happening in terms of the equipment demand versus consumables. And you mentioned the policy and funding change headwinds Kind of how have you seen those play out affecting customer demand in the past kind of couple of quarters? Just trying to understand if that headwind is getting worse or it's holding steady and, you know, what does it mean as we're going into next year, please?
Illuminae Charoyer: Yeah, thanks, Julian, for the question. So the AHS segment overall, just maybe to break it down, The software part of the business, really strong, continues to do really well. So we're quite pleased and excited about that acceleration in that part of the business. With respect to capital equipment in the AHS segment, we talked last quarter about, to your point, the reimbursement and funding policy changes and how that's costing some of these U.S. hospitals to defer capital equipment purchase. What we've seen since then is been encouraging, which is sequential improvement in demand for healthcare capital in North America. Based on just more certainty around legislative conditions that they're operating under, they're still walking through the full kind of long-term effects of the OB-3 Act, but we certainly see improvement in the demand patterns. Significantly in September especially, Because we have a funnel of deals and we know what things were deferred. And we began to see more and more of those get funded in September. And we expect that trend to continue through the rest of the year. So the sequential improvement in that capital equipment purchase we quite like. And we see the same sequential improvement in consumables as well. And our biggest markets continue to grow. in consumables. So overall, I'd say software doing well. The capital equipment piece, we're seeing sequential improvement, and that's quickening in September and into October as well. And then the consumables continues to be solid.
Julian Mitchell: That's great, thanks, Illumide. And maybe one for Mark, just very much a CFO-type question, so apologies for that. But the tax rate outlook, I think this year's sort of overall adjusted P&L tax rate is maybe 14%, something like that. I just wondered, is that sort of a normal run rate in the future, kind of best view on the next sort of year or two, any perspectives on that you could provide?
Mark Okerstrom: Happy to, always happy to answer your CFO questions. I think it's a good framework to think about, you know, right now, mid-teens. You know, the Pillar 2 framework You know, proposals that are out there, you know, there is some risk that to the extent that the U.S. is not excluded from that, which is the current thinking, although it's not written into law, that we could see something drift higher. But right now, from what we see, I think mid-teens is a good way to model the tax rate through 2026 at least.
Julian Mitchell: Great. Thank you.
Brock: You're welcome. Thanks, Jeanette. The next question is from Steve Tusa of JP Morgan. Please proceed with your question.
Steve Tusa: Hey, good afternoon and congrats on a solid quarter. Good execution.
Illuminae Charoyer: Thanks, Steve.
Steve Tusa: Thanks, Steve. The software business, the foul business, what are you guys seeing in the other businesses? I mean, I think you mentioned some of the, you know, construction, I guess, related drags. But are you seeing, you know, how are your customers kind of treating your part of the budgets there from a kind of an IT spending perspective? What do you guys see in there?
Illuminae Charoyer: Yeah, thanks, Steve. So, file overall, we like, we continue to see growth in that platform, so we quite like that. And the components of that, the – The service channel brand, really great pull through. We talked about some of the AI-powered work order insights we're adding to that platform, which is an expansion for existing customers. They love that. I think for customers, they view file software as a good way to scale the impact of AI because we have real networks built around those businesses. The IT spending around that, to the extent that we're helping them capture the value of AI, is really, really strong right now. So we quite like that. And then, you know, the Gordian software part, which is really around planning, facility planning software, also continues to do really well. We talked last quarter about the new products we launched, assessment and capture planning, The other growth in that business has been terrific. Separate from the procurement part of Gordian, that's been a terrific story for us from a software point of view. And then our current continues the arc of improvement that we've talked about over several quarters now. So overall, I think just given the nature of what our software does for customer and the fact that in the grand scheme it's a small spend with very high return on investment, that helps them on AI monetization and getting real value out of AI use cases. It's been a strong part of our story. And that's why we said the recurring revenue part of the company has been growing much faster than the fleet average.
Steve Tusa: Got it. So Fowl grew what in the quarter? Was Fowl above the, like, what was the organic at Fowl in the quarter in total?
Illuminae Charoyer: Yeah, so five grew in total in the quarter, and you can think about it as helpful to the fleet average.
Steve Tusa: Okay, got it. Thank you.
Illuminae Charoyer: Thanks, Steve.
Brock: The next question is from Andy Kabowitz of Citigroup. Please proceed with your question.
Andy Kabowitz: Hey, good morning, everyone, and good afternoon.
Illuminae Charoyer: Good morning, Andy.
Andy Kabowitz: So I think one of the primary goals you have or you had as you split is to simplify your overall business. So obviously the first quarter out of the gate with good margin is a good signpost for that, but maybe talk about where you are in terms of that self-help. I know it's early, but should we get increasing impact from that simplification as we go into 26?
Illuminae Charoyer: Yeah, thank you. I think the short answer is yes. If you think about what we've laid out as our plan here. The plan is we have a simpler company in these 10 brands, which means, frankly, we can simplify how we run the company, free up more time to spend with customers and to spend on growth. And like Mark mentioned, we've also created space in our P&L, as you saw with the big margin expansion in Q3, so we can actually put some more investment behind this growth idea. So all of that's in motion right now. would expect that to keep building momentum for growth as we come out of this year. And then I'd say, secondly, the other thing that's been quite important in this change with the company is the capital allocation strategy. So not only are we going to grow the company faster and the The seeds we're planting around products, commercial and requiring value is playing true on that. But we are also going to significantly shift how we think about capital allocation. And you saw that with the share approaches that we did in Q3 here. And as we go forward, you're going to see that balance continue to play out. And so we're one quarter in, barely 100 days into the journey, and I would expect that the best is still ahead of us here.
Andy Kabowitz: Helpful. And then could you give us a little more color on what you're seeing in demand by region? I think you asked pretty good. I think you mentioned Western Europe maybe downshifted a little. China, like what are you seeing across here and markets by geography?
Illuminae Charoyer: Yeah, I think you have it generally right. I'd say the style of the show continues to be North America, really strong markets. performance in North America. I think part of that's the market, part of that's kind of our team really have pushed hard from an innovation point of view in some of the best end markets, you know, data centers and so on in the U.S. especially. But also, you know, also just the market conditions have been more favorable for us. And then on the other end, you know, I'd say Western Europe especially has been the softest market for us. And that's been the case recently. most of the year. Q2 got a little bit better in Western Europe, but then that didn't really sustain in Q3. So we're not expecting anything to get dramatically better in Western Europe for the rest of the year. So we've kind of planned that in here, and anything better will be upside for us. And then the rest of the world was just mixed and generally stable, I would say, in China and and mixed everywhere else. So North America really good, Western Europe really soft, everything else in the middle.
Andy Kabowitz: Appreciate the color.
Illuminae Charoyer: Thanks.
Brock: The next question is from Jeff Sprague of Vertical Research Partners. Please proceed with your question.
Jeff Sprague: Hey, hello, everyone. Thank you. I just want to get a little bit better sense of maybe the margin trajectory. First off, can you just elaborate a little bit more? You said there was some one timers in the quarter and I don't know if it was a change in capitalization policy or something. Did that all run through corporate? And then essentially you're saying that you're using that quote unquote benefit in Q3 to spend for growth in Q4. You just put a little bit more color or detail around that and correct me if I'm wrong there.
Mark Okerstrom: Yeah, sure. Happy to, Jeff. So there were a few one-timers in the quarter. There were two primary drivers. One was just increased capitalization rates at some of our software companies as they were building new product that was not yet sort of deployed into live production. So that was one impact. That basically lowers R&D and then ultimately will come back in the future as that's amortized in. The second was that we did have some adjustments to incentive compensation, and that was a good guy as well. Those items hit a combination of the segments and the corporate costs. The expectation, even though we are actually making direct cost reductions to actually fund growth, is that overall OPEX will step back up in the fourth quarter as we don't We repeat some of these one-timers as we start to pull in some of the investment ideas that we've got as part of the strategic planning exercise and annual planning exercise that Illumiday laid out. But we're going to maintain discipline and expect to still have a strong margin profile. But overall, OPEX should pop back up a bit in the fourth quarter.
Jeff Sprague: I mean, trying to triangulate between what you gave us and making an educated guess on interest expense and everything and the share count, it looks like you're sort of guiding segment-level margins, I don't know, kind of flat-ish in Q4 on a year-over-year basis. Is that correct?
Mark Okerstrom: I think you're in the zone. you're in the zone, you're going to get year-over-year basis out of the corporate, or year-on-year expansion out of the corporate cost. But you're, you know, you're broadly in the zone. You'll see some pressure and gross margin, particularly at iOS, that then is, you know, largely offset sort of below, you know, below the gross margin line.
Jeff Sprague: Right, right. Okay, right. Thank you for that help. Appreciate it.
Brock: Yeah, you're welcome. The next question is from Joe O'Day of Wells Fargo. Please proceed with your question.
Joe O'Day: Hi, thanks for taking my questions. I wanted to just get a little bit more color on comments around giving brands more growth oxygen, which sounds like an exciting initiative. You know, we, I guess, saw the Q3 R&D down, but maybe that's a little bit more non-repeat. I'm just curious in terms of, you know, what exactly is encompassed in sort of resourcing the growth oxygen for, you know, 10 operating brands and and how to think about the time of that sort of flowing through to organic growth kind of impact.
Illuminae Charoyer: Yeah, thanks for that. So, maybe just describe what it is that we've done. So, what we've done the first 100 days here is we've gone through our strategic planning process with each of our 10 brands. And the nature of that is really digging deep to find the best ideas for organic growth acceleration that maybe we've underleveraged so far. And it may be really compelling enhancement products for customers. It could be commercial capacity expansion in attractive markets like data center or India. It could be expansion to add-on services or software offerings for customers that we just haven't had the space in our P&L to get to. So we went through a process to really assemble all of those ideas across our brands. And I'm just incredibly impressed by this slate of pragmatic and actionable ideas that that came out from that process. So we now have this funnel of terrific ideas that we're getting after very aggressively. And what we've then done is to say, look, we are going to be very disciplined in assessing which of those have the highest confidence and the best return potential. And for those ones, we'll make space in the P&L. That's what we mean by growth oxygen, to make to fund those and to get them done. So some of the margin expansion we got in Q3 that we talked about, we are going to save some of that to invest over the course of Q4 here to really think about it as a surge in getting those great ideas executed faster. So as we go into 26, they're having a lot of impact, keeping in mind that some of them are short time to impact things like commercial capacity ad, some of which are marketing demand gen ad. So we feel quite good about the setup and the space we've created in the P&L to get after this and and really give us businesses more, as we call it, growth oxygen that maybe they've had historically when we've been really tight across the board. But we're just really being intentional in planting seeds that will power the growth. The case that we've made is faster growth, and so we're planting the seeds for that.
Joe O'Day: And then on – organic growth composition and sort of thinking about the price and volume piece and volume kind of slightly down in the quarter. Is the setup that you think the volume decline rate is actually a little steeper into the end of the year? Is that primarily comps? And then just any color on where you see the best opportunity for volume to get a little bit better, maybe areas that you're watching most closely.
Illuminae Charoyer: Yeah, I mean, so, again, a few ways to think about that. One is we like what we're seeing from pricing this year because I think in many ways that's a reflection of the value of those brands. And some of it has been the benefit of tariffs and recovering that. But underneath all of it, it's been an affirmation that we can get priced. in those businesses. So we expect that to continue. And the exciting thing for us is a lot of the growth ideas I talked about are really about volume. And I would say across our businesses, we see a real upside from volume. And I think if you think about our biggest brands in fluke and the AHS segment, those are areas where we have very specific ideas that can help with volume growth over the next year. the next year here going into 26. So we certainly expect the price, you know, kind of strength to continue to be a big contributor to our growth. And then the volume piece of the math will get better over the course of our journey here the next year to three. So that's what we would expect.
Joe O'Day: Thank you.
Illuminae Charoyer: Thanks.
Brock: The next question comes from Chris Snyder of Morgan Stanley. Please proceed with your question.
Chris Snyder: Thank you. I wanted to follow up on some of the Q4 commentary, and I think you guys said you expect organic growth to moderate in Q4 relative to Q3. Is that just a function of a more difficult comp, or did some of the Q2 disruption get pushed into Q3 revenue, so maybe that was a little bit overstated versus demand? Any color there would be helpful. Thank you.
Mark Okerstrom: Sure, happy to answer that, Chris. You know, there are a few things that are happening. One is that in Q4, we do have a little bit of a tougher comp. If you look at the script commentary from last year, you know, we talked about some pull forward from Q2 into Q4. You know, I think it's particularly acute in the iOS segment. There was, I think, a little bit of a snapback in Q3 in terms of just some of that $30 million coming back. I would just say, though, overall, the trends that we're seeing across the iOS segment and the AHS segment are broadly consistent. They're encouraging. I think, as Illuminae said, we've got lots of optimism for better volume growth as we step into 2026. But we do have some timing-related impacts that are sort of shifting things from Q2 to Q3 and then out of Q4.
Chris Snyder: Thank you. I appreciate that. Maybe just to follow up on AHS, from the outside looking in, it's very difficult to kind of have a sense for the performance versus the healthcare policy and funding challenges that could be coming or maybe leaving the market based on the policy. I guess, you know, it seems like you guys think AHS will have another pretty solid quarter here in Q4. But, you know, I guess what gives you guys confidence that, you know, the North America healthcare spend, you know, can be supportive or resilient, you know, through a, you know, just a kind of a choppy, hard to predict policy backdrop? Thank you.
Illuminae Charoyer: Yeah, thanks for that. I mean, overall, we like the AHS path that's set up here. So if you think about it, this time last year, the AHS segment grew 9% organic growth in Q3 of 24, 6% for the year overall. And so we know what the capacity of this business is. And despite the choppiness of 2025 with all the healthcare-related policy changes, we Our businesses continue to do the right things for our customers. The depth of customer loyalty, customer support, and I've experienced this personally just being out with a lot of our customers in that segment, is incredibly strong. So we like our setup. We like what we're doing with respect to innovation. We like what we're doing with respect to kind of the commercial engagement with customers and and recurring value that we're adding to those customers across all our brands. So that piece we really liked. And then if you think about the fundamental kind of spend and demand profile of healthcare in the U.S., Whatever is going on in the end, it still comes down to the basic fact that we've got aging demographics, we've got increasingly sophisticated healthcare options and intervention options for these aging demographics, a lot of which have two or more chronic conditions, and we continue to have shortage in provider capacity. That means the kinds of solutions that we bring to drive productivity and safety are going to be incredibly supported by this tailwind over the next three to five years. So irrespective of the choppiness of policy decisions in 2025, we like what we're doing on innovation, on commercial and recurring value, and we like the underlying sustained circular trends that make this healthcare, and especially the industrial part of healthcare, that we focus on be a good market to be in. So that's kind of where we focus is play for what's going to create value beyond quarter-to-quarter noisiness in the space. We really like the business, and we think we're well set up.
Chris Snyder: Thank you. I appreciate that.
Illuminae Charoyer: Thanks.
Brock: The next question is from Jamie Cook of Truist Securities. Please proceed with your question.
Jamie Cook: Hi, good afternoon, I guess. A couple quick, two quick questions. One, you know, you talk about forward of accelerated innovation, acceleration, commercial acceleration, like all these opportunities to sort of ignite growth profitably. Just to be clear, I mean, it doesn't sound like you embed any of that in your guidance. So just wondering if there, you know, if there's opportunity for upside, you know, on the top line as some of these initiatives go through. And then just my second follow-up question, the 63.6 million and other on the adjusted operating profit, what, I mean, that's usually trends, I guess, in the low 30s. Can you just break apart, like, what was in that number and then what's implied for the fourth quarter? Thank you.
Illuminae Charoyer: Great. Thanks for the question. I'll take the first part, and I'll have Matt take the second one. So, you know, the way we think about it is we laid out at our investor day in June that financial framework for the two-year period of 26-27. The premise of that is the company we now have is going to be 3% to 4% organic growth, and then after 26-27 gets better than that. And then we'll have margin expansion, 5,200 business points, And then I just said EPS growth. That's high single-digit class growth. So that financial framework benefits from all of these 40 accelerated initiatives. That's what gives us confidence that that financial framework remains intact. And so that's where you're going to see the impact of it. With respect for the guide for this year, you know, we feel good about the way we've reflected the macro conditions and all the forces at work across the three areas we've talked about on tariffs and healthcare spending and state and local government spending. And that's all reflected in in the guide for this year. But the way to think about our 40% accelerated strategy and the impact of that is it really is what gives us complete confidence in the financial framework that we laid out for 26-27. And I'll let Mark touch on the second part of the question.
Mark Okerstrom: Yeah, I think, Jamie, we'll get back to you on that. I think you're referring to that other operating income in the AHS segment. So just give us a bit and we'll circle back with you on that. Maybe we can go to the next question.
Brock: The next question is from Joseph Giordano of TD Cowen. Please proceed with your question.
Joseph Giordano: Hi. Good afternoon. This is Chris on for Joe. You'd called out the growth, the double-digit growth in recurring revenue, and you noted that it was outpacing the overall average. Where do you see recurring revenue potentially ending up as a percent of total in the longer term? What are some key levers that you have in both segments to sustain that above-corporate average trajectory?
Illuminae Charoyer: Yeah, thanks for the question. So we like the recurring revenue percentage continuing to go up, and we've deliberately not set – a zillion on how high it goes. So we expect it to continue to grow and with no limits on what's possible over time. The second thing I'd say is if you think about the pieces of our company today that are still not recurring, and then you think about how quickly those can change, we still do have some incredibly powerful professional instrumentation offerings at Fluke. That's the biggest chunk of our business that's not recurring. Now, that business was almost 0% recurring 10 years ago. And if you go back five years ago, it was probably 5%, 6% recurring. Today, it's 15% recurring. So the biggest lever for us to keep driving recurring revenue is continuing to attach more recurring things at Fluke. And, you know, we also have Some examples from businesses that were mostly transactional, like Industrial Scientific, 10 years ago, and we've shifted those to more hardware-as-a-service recurring offerings. And, again, that gives us a little bit of a template of some of the things we could do for some of our offerings at Fluke as well is shift them to more of a hardware-as-a-service offering. So that's probably the single biggest bucket of revenues that will move the needle the most as we shift more of the company towards recurring. Now, we're going to be – intentionally, it's one of our three pillars for the accelerator that is driving recurring customer value.
Joseph Giordano: Thanks very much.
Brock: The next question. Great.
Mark Okerstrom: Sorry. Operator, maybe I'll just circle back on Jamie's question. That incremental expense was predominantly related to separation-related stock compensation matters, so fair market adjustments as well as the acceleration of certain executive compensation associated with the transition of leadership. Great. Thanks.
Brock: Thank you. The next question. is from Andrew Buscaglia of BNP Paribus Asset Management. Please proceed with your question.
Andrew Buscaglia: Good afternoon, everyone. Good afternoon. You know, you guys, there's a lot of noise on the margin side, Q3 to Q4, but I'm looking high level into 26. How volume depends on margins? And can we count on some of these savings helping you expand in a low or no volume environment. And then another question is, any update on other incremental stranded costs we'll see fall out in 26 or where do we stand with that side of the story?
Mark Okerstrom: Yeah, thanks for the question. At this point, I would just turn your attention to the financial framework we laid out at Investor Day. which was, again, 3% to 4% revenue growth, 50% to 100% basis points of adjusted EBITDA margin expansion and high single-digit plus adjusted EPS growth. We're in the middle of annual planning right now, and really we're just trying to strike the balance between driving the appropriate amount of margin expansion along with accelerating growth. And we'll be able to give you a little bit more color on that, obviously, on our next call. In terms of stranded costs, we're almost there. We took some other actions, as you saw in the third quarter. There's some stock comp-related stranded costs that we'll be sort of working out. A lot of that sits in the segments. But we're almost there. We'll probably, you know, in six to 12 months, we'll have the rest of it out. And as a reminder, I think we said we had 25 million that was out and there was 25 million left to go. There's probably half of that remaining for us to take out over the course of the next six to 12 months.
Andrew Buscaglia: Okay, great. Thank you. You're welcome.
Brock: This now concludes our question and answer session. I would like to turn the floor back over to Olumide for closing comments.
Illuminae Charoyer: Thanks, Brooke, and thank you all for joining us. We really appreciate your interest and thought. We could not be more excited about the journey we're just starting here. It's still early. We realize that some of you know us and some of you are new to us, but we are incredibly excited. We have a simple playbook here. We've got a great portfolio. We believe we're going to drive faster, profitable organic growth. from this portfolio. We are going to continue to be very disciplined in terms of leverage down the P&L and our cost discipline with FBS helping us through that. And our capture allocation approach is going to be intelligently positioned to balance share repurchase and smaller bolts on M&A. And we believe that that formula and us doing what we said we'd do on that and building trust and maintaining trust will do incredible things for shareholder value creation in the next three years. So that's exciting for us. We hope it is for you as well. Thanks for joining, and we'll see you next time.
Brock: Ladies and gentlemen, thank you for your participation. This does conclude today's teleconference. You may disconnect your lines and have a wonderful day.
